Ignite Creation Date:
2024-05-06 @ 9:36 AM
Last Modification Date:
2024-10-26 @ 12:17 PM
Study NCT ID:
NCT03025542
Status:
COMPLETED
Last Update Posted:
2022-10-28
First Post:
2017-01-17
Brief Title:
A Study to Evaluate the Pharmacokinetics PK Pharmacodynamics PD and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis
Sponsor:
UCB Biopharma SRL
Organization:
UCB Pharma
Study Overview
Official Title:
A Multicenter Randomized Subject-Blind Investigator-Blind Study to Evaluate the Time Course of Pharmacodynamic Response Safety and Pharmacokinetics of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status:
COMPLETED
Status Verified Date:
2022-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 2a multicenter randomized subject-blind investigator-blind study to investigate the pharmacokinetics PK pharmacodynamics PD and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2016-002368-15 | EUDRACT_NUMBER | None | None |